Strategic FP&A Director

Epalinges, Switzerland

June 2022 - Present

1 in 3 people will be diagnosed with cancer in their lifetime (according to cancer.org). Therefore, it is critical to detect it when it matters most. Powerful new blood-based cancer detection technologies such as ctDNA are emerging into clinical use, easing the screening process. Furthermore, the information gathered from these analyses will take our awareness of cancer to the next level unlocking new possibilities. However, all of these new technologies add a lot of complexities to the daily clinical workflow requiring new tools for easy access and usability. Hedera platform solves that challenge, giving a streamlined experience for clinicians to access information and liquid biopsy tests in early detection, therapy selection and recurrence monitoring.

Commercial Finance Manager, Strategic Finance

France

July 2020 - June 2022

Global Sales Manager, Alamut Business Line

Bidart, France

April 2019 - July 2020

Co-Founder

Soorts-hossegor, France

April 2017 - April 2019

Associate, Investments Strategy

London, United Kingdom

July 2014 - June 2016

Analyst, Latin American Team

Geneva, Switzerland

July 2011 - June 2014

Global Communication (Global Equities & Commodity Derivatives)

Paris, France

January 2010 - July 2010

Student Work Training Programme

The Hague, Netherlands

September 2008 - September 2008

Volunteer

Hanoi, Viet Nam

June 2008 - June 2008